ClinicalTrials.gg
CompletedNCT04525911ALCOVIDUpdated Oct 29, 2026

Assessment of Long-term Impact Post COVID-19 for Patients and Health Care Professionals of the European Hospital

An interventional study of Diagnostic Test: serology test for COVID-19 in Covid19, sponsored by Hôpital Européen Marseille. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Hôpital Européen Marseille · Not applicable, Interventional, and Other

How we know

Updated Oct 29, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
214
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 782 studies in COVID-19 with a site in France — 51 open to participants now, 68 under way, 7 of them phase 3. COVID-19 · France.

Enrollment
114th of 294
214 · median 130
Started
2020
with 498 others
No phase
178 of 782
15 open now
Registered
342nd of 782
by date

Among the 782 studies in COVID-19 with a site in France, this one is the 114th largest by enrollment of the 294 interventional ones that give a count, is one of 499 that started in 2020, is one of 178 with no phase, and was the 342nd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

51 of the 782 studies in COVID-19 with a site in France are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 782 studies in COVID-19 with a site in France, or all of them as a file.
02

Study summary

The purpose of the study is to Assess of Long-term impact post COVID for patients and health care professionals.The patients and medical staff will be followed for 2 years in order to provide clinical and paraclinical data not yet published in the literature.

03

Conditions studied

  • Covid19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years,
  • Symptomatic COVID-19 infection confirmed (by RT-PCR or ELISA serology) or probable (CT criteria),
  • Having given free and informed written consent,
  • Being affiliated with or benefiting from a social security scheme.
  • Patients / caregivers may be included in several ancillary studies at the same time.

Exclusion criteria

Exclusion Criteria:

-Subject to a measure for the protection of justice

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    Symptomatic COVID-19 infection confirmed or probable

    Patients and medical staff having symptomatic COVID-19 infection confirmed (by RT-PCR or ELISA serology) or probable (CT criteria)

    Diagnostic Test: Diagnostic Test: serology test for COVID-19

Interventions

  • Diagnostic testDiagnostic Test: serology test for COVID-19

    a serology test will be performed at M3

06

What researchers measure

Primary outcomes

  1. Evaluation of post-traumatic stress symptoms (Post traumatic Stress Disorder (PTSD) scale) at M3 for patients and caregivers

    measure used to assess symptoms of post-traumatic stress disorder. Individuals should rate their experience with each of the 17 symptoms of PTSD on a scale of 1 to 5 (1 = not at all, 2 = a little, 3 = moderately, 4 = a little, and 5 = extremely) versus to a specific traumatic event

    Time frame: 3 months

Secondary outcomes

  1. Evaluation of post-traumatic stress symptoms (PTSD scale) at M12 and M24 for patients and caregivers

    Time frame: 12 and 24 months

  2. Change from M3 in the score of the mental (MCS), physical (PCS) components and the scores of the individual domains of the questionnaire SF36 to M12 and M24 for the entire study population

    Time frame: 12 and 24 months

  3. % of patients presenting a positive result by ELISA serology (= without distinction of IgG, IgM and IgA)

    Time frame: 3 months

  4. Comparison of M0 chest CT results at each follow-up for the entire study population

    Time frame: 24 months

Other outcomes

  1. Change from M3 score measuring anxiety (HAD-A) and depression score (HAD-D) to M12 and M24 for patients and caregivers.

    HAD-A score measuring anxiety (example "I feel tense or nervous") and HAD-D score for depression (example "I have the impression of operating in slow motion"). * 7 or less: no symptoms * 8 to 10: doubtful symptomatology * 11 and more: definite symptomatology.

    Time frame: 12 and 24 months

  2. Change from M3 in the B-IPQ score at M12 and M24 for patients and caregivers.

    The Brief Illness Perception Questionnaire (B-IPQ) includes 9 items that assess different components of "perception of the disease"( score 0 to 10 for each items)

    Time frame: 12 and 24 months

  3. Evaluation of the microbiotic signature according to the severity of the disease at M3, M6 and M12

    Time frame: 6 and 12 months

  4. Evaluation of the fatigue EVA score and quality of life (SF36) at M6 and M12

    score from 0 to 10 (0 not tired, 10 max tired)

    Time frame: 6 and 12 months

07

Study locations

1 site
  • BENNANI
    Marseille, 13003, France
08

References and documents

Publications

  • Escoda T, Chiche L, Faralli H, Cohen F, Halfon P, Pegliasco H, Rebaudet S; ALCOVID consortium. Cluster analysis of post-COVID-19 physical and mental health outcomes 3-6 months after SARS-CoV-2 infection: results of the French Prospective ALCOVID Cohort Study. BMJ Open. 2025 Feb 11;15(2):e089136. doi: 10.1136/bmjopen-2024-089136. PubMed 39933809 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Feb 2022, 17 months.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 17 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Aug 2022 → Feb 2022 and completion Oct 2022 → Feb 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2020
First posted
Aug 25, 2020
StartActual
Aug 26, 2020
Primary completionActual
Feb 9, 2022was Aug 2022
CompletionActual
Feb 13, 2023was Oct 2022
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 29, 2026
Primary completion
Aug 2022→Feb 9, 2022 (actual)
Oct 29, 2026
Study completion
Oct 2022→Feb 13, 2023 (actual)
Oct 29, 2026
Eligibility
Revised
Oct 29, 2026
Design
Study type Observational→Interventional
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Status unknown→Completed
    Primary completion Aug 2022→Feb 9, 2022 (now actual)
    Study completion Oct 2022→Feb 13, 2023 (now actual)
    Eligibility Revised
    Design Study type Observational→Interventional
    + 4 other changes: index terms, arm descriptions, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04525911
Lead sponsor
Hôpital Européen Marseille
Responsible party
Sponsor
First posted
Aug 25, 2020
Start date
Aug 26, 2020
Primary completion
Feb 9, 2022
Completion
Feb 13, 2023
Last update
Oct 29, 2026

Study contacts

Hervé PEGLIASCO
principal investigator · Hôpital Europeen Marseille

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion